SCHEMBL264597

SCHEMBL264597

CCOc1ccc(Cl)c(-c2ccc(NC(=O)c3conc3C)nc2N)c1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN10A Q9Y5Y9 13/20 0.81
SCN9A Q15858 3/20 0.55
SCN5A Q14524 2/20 0.55
SCN2A Q99250 2/20 0.55
SCN3A Q9NY46 2/20 0.55
SCN1A P35498 1/20 0.54
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
NPC1 O15118 2/20 0.39
TP53 P04637 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
GCK P35557 1/20 0.39
ALDH1A1 P00352 1/20 0.39
KMT2A Q03164 1/20 0.39
ATM Q13315 1/20 0.39
CTSD P07339 1/20 0.39
TSHR P16473 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14237757 0.91 SCN10A (0.82) SCN10ASCN9ASCN5ASCN2ASCN3A
SCHEMBL263118 0.90 SCN10A (1.00) SCN10ASCN9ASCN5ASCN2ASCN3A
SCHEMBL264547 0.86 SCN10A (0.80) SCN10ASCN9ASCN5ASCN2ASCN3A
SCHEMBL14237554 0.86 SCN10A (0.80) SCN10ASCN9ASCN5ASCN2ASCN3A
SCHEMBL14237664 0.85 SCN10A (0.72) SCN10ASCN9ASCN5ASCN2ASCN3A
SCHEMBL263933 0.85 SCN10A (0.77) SCN10ASCN9ASCN5ASCN2ASCN3A
SCHEMBL263117 0.84 SCN10A (0.76) SCN10ASCN9ASCN5ASCN2ASCN3A
SCHEMBL14237538 0.84 SCN10A (0.75) SCN10ASCN9ASCN5ASCN2ASCN3A
SCHEMBL263424 0.81 SCN10A (0.73) SCN10ASCN9ASCN5ASCN2ASCN3A
SCHEMBL14237458 0.81 SCN10A (0.81) SCN10ASCN9ASCN5ASCN2ASCN3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2183241-B1 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LTD (GB) 2012-12-19 EP claimed
US-8134007-B2 Pyridine derivatives PFIZER INC. (US) 2012-03-13 US claimed
JP-4657384-B2 2011-03-23 JP claimed
JP-2010526050-A 2010-07-29 JP claimed
EP-2183241-A2 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS Pfizer Limited (GB) 2010-05-12 EP claimed
US-20090048306-A1 PYRIDINE DERIVATIVES PFIZER, INC. (US) 2009-02-19 US claimed
WO-2008135826-A2 2 -PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LIMITED (GB) 2008-11-13 WO claimed
EP-2183241-B1 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LTD (GB) 2012-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048306-A1 PYRIDINE DERIVATIVES SDHA, P2RX4, P2RX3 SCN10A 358/4885SCN9A 491/4885SCN5A 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.